Use of monoclonal antibodies for the histopathological diagnosis of human malignancy (original) (raw)
Related papers
Cancer, 1980
Pathologic samples from 34 cases of human solid malignancies were tested for reactivity with monoclonal anti-human leucocyte antibody, designated 2DI. This antibody detects a human leucocyte antigen (HLe-I) that is expressed strongly on B and T lymphoid cells and weakly on early hemopoietic cells, but is not found on normal mesenchymal and epithelial tissues. This study demonstrates the use of this reagent in cryostat sections of tumor samples using indirect immunofluorescence in combination with other lymphoid markers such as anti-T cell serum, anti-Ia-like serum (detecting p28, 33 "B cell associated" membrane antigen) and antisera to different immunoglobulin isotypes. Tumor cells from all 12 cases of epithelial malignancies and sarcomas were HLe-I-although adjacent (normll) lymphoid cells showed strong positive staining. In contrast, 20 cases of lymphoma (B-as well as T-cell types) were HLe-I+. Two other malignancies involving the lymphoid system were HLe-I-and failed to express any of the other lymphoid markers tested. Cancer 46:2640-2647, 1980. LTHOUGH HISTOPATHOLOGIC DIAGNOSIS of human A solid malignant tumors can usually be made confidently, a proportion of cases present difficulties even to experienced morphologists. Non-Hodgkin's lymphomas, which diffusely replace normal tissue architecture, may be difficult to distinguish morphologicly from undifferentiated metastatic carcinomas. ' This distinction is of clinical significance, since the response of these malignancies to therapeutic efforts is different. Recent advances in immunologic techniques have enabled a more precise identification of the non-Hodgkin's lymphomas. Cytoplasmic immunoglobulin (Ig) can frequently be demonstrated by immunoperoxidase technique in paraffin-embedded tissues. * Bradstock, Beverly, and Janossy. Unpublished observations. 23. Weissman IL, Warnke R, Butcher EC, Rouse R, Levy R. The lymphoid system. Its normal architecture and the potential for understanding the system through the study of lymphoproliferative diseases. Hum Pathol 1978; 9:25-45. 24. Winchester RJ, Ross GD, Jarowski CI, Wang CY, Halper J, Broxmeyer HE. Expression of la-like antigen molecules on human granulocytes during early phases of differentiation. Proc Natl Acad Sci USA 1977; 74:4012-4016. 691587-593. 298~481-486.
Selection of monoclonal antibodies detecting serodiagnostic human tumor markers
Journal of Immunological Methods, 1985
Monoclonal antibodies (MAbs) were selected for specific binding to spent media of cultured tumor cells. Out of more than 12,000 hybridomas screened, 19 were selected in preliminary inhibition assays for secretion of MAbs which detected antigens in cancer patients' sera. Antibody CO 29.11, which was studied in detail, bound to an antigen shed and expressed by adenocarcinoma cells of colon, stomach, pancreas and urinary bladder. CO 29.11 bound to purified sialylated Lewis a (Le a) antigen but to a different epitope and with a higher binding affinity than the MAb CA 19-9. CO 29.11 but not CA 19-9 bound weakly to unsialylated Le a antigen. In double-determinant radioimmunoassay with sera of patients with colorectal carcinoma, CO 29.11 was found to be a more sensitive marker than CA 19-9 for the detection in serum of sialylated Le a antigen.
Monoclonal antibodies in the management of carcinoma patients
Medical oncology and tumor pharmacotherapy, 1991
The use of monoclonal antibodies (MAbs) in the clinical management of carcinoma patients is reported in the present review. Among the various MAbs generated, MAb B72.3 (LTIB, National Cancer Institute, U.S.A.) has been extensively used in clinical trials either for antigen identification (TAG-72) in sera, or for tumor localization in carcinoma patients. Serum assay results, in colorectal cancer patients, showed the usefulness of the MAb B72.3 in monitoring the clinical course of the malignant disease. Its specific tumor localization (70% of the biopsy specimens) and the immunoscintigraphy studies, after in vivo administration, have also been discussed. The positive results obtained, markedly contributed in the development of a new intraoperative methodology termed "radioimmunoguided surgery".
Cancer research, 1987
Monoclonal antibody 17.13., derived from a fusion of splenocytes of a BALB/c mouse immunized with a surgically resected poorly differentiated human laryngeal recurrent squamous cell carcinoma (SCC) with mouse Sp2/0 cells, is an IgM-K which recognizes a cytoplasmic component of basal cells. Tissue sections of malignant and normal squamous epithelium, tumors of nonsquamous origin, and normal and malignant cytological specimens were tested with an immunoperoxidase assay. Seventy-nine of 81 (98%) SCC of the head and neck, 26 of 26 (100%) SCC of the cervical and female gynecological tract, 29 of 30 (97%) SCC of the lung, 19 of 19 (100%) SCC of the oral cavity, and 17 of 17 (100%) SCC-involved neck lymph nodes reacted strongly. Various carcinomas from breast, colon, ovary, and others were unreactive. In normal squamous epithelial tissues, monoclonal antibody 17.13. reacts only with basal cells but not the cells above the basal layers. Normal tissues from heart, liver, spleen, kidney, blad...
Use of four monoclonal antibodies to detect tumor markers
Cancer, 1986
A combined panel of monoclonal antibodies to tumor markers was examined in the sera of 454 cancer patients to compare their reactivity. At least one of the four tumor-associated markers (CEA [caranoembryonic antigen], CA 19-9, CA 125, and SLEX [sialylated Lewisx epitope]) was positive with the sera of breast (43%), lung (64%), ovarian (54%), and colorectal (57%) cancer. Each tumor marker's reactivity was distinct in different patients, indicating that different epitopes were being detected. The number of tumor markers that were positive was associated with advancing stages of disease. In advanced stages with distant metastasis, 13% of the patients reacted with all four markers, whereas none of the early-stage patients did. In 14 cases of disease progression, the tumor markers increased with no instance of decrease. Among ten patients with regression, seven showed a decrease in tumor markers and three showed an increase. The authors conclude that the use of four tumor-associated markers expands the number of patients with a positive marker, thereby permitting the monitoring of some patients. Among 60 normals, one showed a weak reactivity with CEA and one with CA 125. Eventually, with more markers, it should be possible to monitor all patients.
The current status of monoclonal antibodies in the diagnosis and therapy of cancer
Current Problems in Cancer, 1986
Beginning in 1987, CURRENT PROBLEMS IN CANCER will welcome a new Editorial Board, incorporate an improved physical design, and be published bimonthly, rather than monthly. These significant improvements in CURRENT PROBLEMS IN CANCER are a direct result of extensive market research conducted among our readers. The new Editorial Board is headed by Charles M. Haskell, M.D., Professor of Medicine and Surgery at the UCLA School of Medicine. A group of preeminent specialists in oncology, surgical oncology, and radiation therapy join Dr. Haskell as associate editors of CURRENT PROBLEMS IN CANCER:
Monoclonal antibodies--therapeutic and diagnostic uses in malignancy
The Western journal of medicine, 1985
Murine monoclonal antibodies represent an attractive type of antitumor therapy because of their potential for exquisite specificity, production in large, pure quantities and mediation of in vivo cytotoxic effects. With maturing monoclonal antibody technology has come the use of these antibodies in clinical studies in patients with malignancy. These trials have established that monoclonal antibodies can be safely administered in large doses, that their pharmacokinetics and tissue penetration can be predicted and that in some instances a therapeutic effect can be produced by their infusion. A number of problems have also been identified by these studies, including antigenic heterogeneity of the tumor, the presence of free serum antigen, the immunogenicity of the xenogeneic antibody, modulation of the surface antigen by the antibody and a finite capacity of human effector mechanisms to mediate cytotoxicity directed by murine antibodies. Other workers are concurrently investigating the ...